<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035889</url>
  </required_header>
  <id_info>
    <org_study_id>19-27108</org_study_id>
    <nct_id>NCT04035889</nct_id>
  </id_info>
  <brief_title>Melatonin for Sleep in MS</brief_title>
  <official_title>A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many people with MS report sleep disturbances. However, objective data on sleep quality in
      MS, such as those obtained using actigraphy, remain scant, as do data about optimal
      therapeutic management. Melatonin is frequently used to improve sleep parameters, both in
      healthy and neurological populations. Altered melatonin regulation and signaling has been
      implicated in MS, through observations including (1) MS risk associated with shift work, (2)
      contribution of melatonin to seasonal risk of MS relapses, and (3) possible reduction of
      endogenous melatonin levels from exogenous corticosteroid administration.

      To the best of our knowledge, no studies have evaluated melatonin vs. placebo as a low-cost,
      low-risk agent to treat sleep disturbance in MS. To test this, we are conducting a randomized
      controlled pilot trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep time</measure>
    <time_frame>4 weeks</time_frame>
    <description>Total sleep time (time in bed spent sleeping after &quot;lights off&quot;)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>4 weeks</time_frame>
    <description>Sleep quality and sleep disturbances assessed by the Pittsburgh Sleep Quality Index and Insomnia Severity Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>4 weeks</time_frame>
    <description>Sleep efficiency: % time asleep while in bed after &quot;lights off&quot;, averaged for mean nightly sleep efficiency
Sleep onset latency time: time from &quot;lights off&quot; to sleep</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to Group 1 will take 2 weeks of melatonin followed by 2 weeks of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to Group 2 will take 2 weeks of placebo followed by 2 weeks of melatonin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 20-70 with a diagnosis of MS by 2010 McDonald Criteria or CIS (clinically
             isolated syndrome), who report sleep disturbance as measured by a score &gt;=5 on the
             Pittsburgh Sleep Quality Index, or more specific insomnia symptoms (a score of &gt;14 on
             the Insomnia Severity Index) over the past month.

          -  Participants must be able to read and write English

        Exclusion Criteria:

          -  Individuals with nocturnal asthma, use of melatonin or another sleep agent in the past
             2 weeks, women attempting conception, relapse or steroids or infusible disease
             modifying therapies (DMTs) in prior month.

          -  Non-English speaking individuals

          -  Individuals with hypertension, impaired liver function, or seizure disorder

          -  Individuals with untreated depression, as determined by a score greater than or equal
             to 8 points on the HADS (Hospital Anxiety and Depression Scale)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riley Bove, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Rowles</last_name>
    <phone>415.502.7209</phone>
    <email>william.rowles@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Rowles</last_name>
      <phone>415-502-7209</phone>
      <email>william.rowles@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Riley Bove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Riley Bove, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Sleep</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Sleep disturbance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

